IMCB Invited Speaker



Speaker: Prof. Gen-Sheng Feng Professor of Pathology and Molecular Biology, University of California, San Diego, USA

Date: 10 December 2013, Tuesday

Time: 2:30PM - 3:30PM

Venue: IMCB Seminar Room 3-46, Level 3, Proteos, Biopolis

Host: Prof. Wanjin Hong

Seminar:

The pro- and anti-oncogenic molecules in liver cancer

Targeted block or inhibition of excessive proliferation signals has been an option in treatment of liver cancer. For example, Sorafenib is an inhibitor of multi-tyrosine kinases, including VEGFR, PDGFR and Raf kinases, which has been used in clinical treatment of advanced HCC patients, albeit with low efficacy and severe side effects. Overall, recurrence and metastasis remain to be the major problem, leading to extremely poor prognosis. The dual roles of signaling molecules in liver cancer may help illustrate the disappointedly low efficacy of therapeutic reagents based on blocking proliferative signals. Our current focus in the lab is on elucidating the molecular mechanisms underlying the pro- and anti-oncogenic effects of molecules in HCC, which may provide fresh view on hepatooncogenesis.

About the Speaker:

Dr. Feng received a PhD degree in Molecular Biology and Microbiology at Indiana University Bloomington. He did a postdoctoral fellowship, awarded by the Medical Research Council of Canada, with Dr. Bryan Williams at the Hospital for Sick Children and Dr. Tony Pawson at Mt Sinai Hospital in Toronto, Canada. Before joining UCSD, Dr. Feng held faculty positions at Indiana University School of Medicine in Indianapolis, and the Sanford/Burnham Medical Research Institute in La Jolla. Dr. Feng has published 129 peer-reviewed research papers, review and book chapters. He has served on MCB and JBC editorial boards and NIH study sections.